Kodiak Sciences Inc.
KOD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001468748
In the last 90 days, Kodiak Sciences Inc. insiders filed 4 open-market purchases and 1 sale; 216 institutions reported holding it in 13F filings for Q3 2026, worth $5.72B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 27, 2025 | Mar 28, 2024 | Mar 28, 2023 | Feb 23, 2022 |
| Operating expenses | $234.4M | $186.8M | $277.3M | $341.4M | $267.1M |
| Research and development | $182.4M | $126.1M | $206.3M | $267.6M | $217.3M |
| Selling, general and administrative | $52.0M | $60.8M | $71.0M | $73.8M | $49.7M |
| Operating income | -$234.4M | -$186.8M | -$277.3M | -$341.4M | -$267.1M |
| Interest expense | $0 | $0 | $13.0K | $18.0K | $22.0K |
| Income tax | $52.0K | $20.0K | $33.0K | $33.0K | $74.0K |
| Net income | -$230.0M | -$176.2M | -$260.5M | -$333.8M | -$267.0M |
| EPS, basic | $-4.32 | $-3.35 | $-4.97 | $-6.39 | – |
| EPS, diluted | $-4.32 | $-3.35 | $-4.97 | $-6.39 | – |
| Weighted shares, basic | 53.2M | 52.6M | 52.4M | 52.2M | – |
| Weighted shares, diluted | 53.2M | 52.6M | 52.4M | 52.2M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 27, 2025 | Mar 28, 2024 | Mar 28, 2023 | Feb 23, 2022 |
| Cash and equivalents | $209.9M | $168.1M | $285.5M | $190.4M | $731.5M |
| Short-term investments | – | – | $0 | $288.5M | $0 |
| Total current assets | $214.8M | $171.9M | $289.3M | $486.0M | $734.8M |
| Property, plant and equipment | $85.3M | $102.2M | $120.5M | $56.4M | $41.3M |
| Total assets | $351.5M | $335.6M | $479.4M | $666.6M | $904.2M |
| Accounts payable | $12.9M | $3.92M | $13.6M | $9.13M | $12.4M |
| Total current liabilities | $45.5M | $25.6M | $41.7M | $52.5M | $64.7M |
| Total liabilities | $194.2M | $185.3M | $213.6M | $230.5M | $240.9M |
| Shareholders' equity | $157.4M | $150.3M | $265.8M | $436.2M | $663.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 27, 2025 | Mar 28, 2024 | Mar 28, 2023 | Feb 23, 2022 |
| Operating cash flow | -$136.0M | -$117.3M | -$154.2M | -$206.5M | -$182.3M |
| Capital expenditures | $506.0K | $375.0K | $41.4M | $37.0M | $17.0M |
| Free cash flow | -$136.5M | -$117.7M | -$195.5M | -$243.5M | -$199.3M |
| Stock-based compensation | $58.9M | $60.2M | $88.6M | $106.0M | $6.14M |
| Investing cash flow | -$506.0K | -$755.0K | $249.2M | -$336.5M | -$38.8M |
| Financing cash flow | $178.3M | $501.0K | $31.0K | $1.90M | $8.18M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 9, 2026 | 65.4M | +23.3% | SEC |
| Aug 6, 2026 | 62.8M | +19.0% | SEC |
| Apr 30, 2026 | 62.6M | +18.6% | SEC |
| Mar 19, 2026 | 61.8M | +17.3% | SEC |
| Nov 6, 2025 | 53.0M | +0.8% | SEC |
| Aug 6, 2025 | 52.8M | +0.4% | SEC |
| May 7, 2025 | 52.8M | +0.4% | SEC |
| Feb 28, 2025 | 52.7M | +0.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.